Background: Reports of neoplasms in Panthera species are increasing, but they are still an uncommon cause of disease and death in captive wild felids. The presence of two or more primary tumor in large felids is rarely reported, and there are no documented cases of ocular melanoma and mammary mucinous carcinoma in African lions.
Case Presentation: An ocular melanoma and a mammary mucinous carcinoma are described in an African lion (Panthera leo). The first tumour was histologically characterized by the presence of epithelioid and fusiform melanocytes, while the latter was composed of mucus-producing cells with an epithelial phenotype that contained periodic acid-Schiff (PAS) and Alcian blue staining mucins. Metastases of both tumor were identified in various organs and indirect immunohistochemistry was used to characterize them. Peribiliary cysts were observed in the liver.
Conclusions: This is the first description of these tumor in African lions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517319 | PMC |
| http://dx.doi.org/10.1186/1746-6148-8-176 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Wearable electrodriven switch actively delivers macromolecular drugs to fundus in non-invasive and controllable manners.
Nat Commun
January 2025
Suzhou Key Laboratory of Nanotechnology and Biomedicine, Institute of Functional Nano & Soft Materials & Collaborative Innovation Center of Suzhou Nano Science and Technology (NANO-CIC), Soochow University, Suzhou, China.
Current treatments for fundus disorders, such as intravitreal injections, pose risks, including infection and retinal detachment, and are limited in their ability to deliver macromolecular drugs across the blood‒retinal barrier. Although non-invasive methods are safer, their delivery efficiency remains suboptimal (<5%). We have developed a wearable electrodriven switch (WES) that improves the non-invasive delivery of macromolecules to the fundus.
View Article and Find Full Text PDFUnveiling the role of ACTL6A in uveal melanoma metastasis and immune microenvironment.
Int Immunopharmacol
January 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou 510060, China; Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China. Electronic address:
Purpose: To predict and evaluate the possible mechanisms and clinical value of ACTL6A in the prognosis and development of UM.
Methods: Bioinformatics analyze the relationship between ACTL6A and immunity in UM, which derived from TCGA, Gene Expression Omnibus (GEO) databases. Tumor-infltrated immune cells were demonstrated using QUANTISEQ and MCP-counter.
Comparison of HDR-brachytherapy and tomotherapy for the treatment of non-melanoma skin cancers of the head and neck.
Radiother Oncol
December 2024
Medical Physics Unit, IRCCS, Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Italy. Electronic address:
Purpose: This study aims to investigate and compare High Dose Rate Brachytherapy (HDR-BT) with Helical Tomotherapy (HT) treatment plans. The focus is on small target volumes near radiation-sensitive organs in the ocular region, to evaluate the advantages of these techniques in treating skin cancer.
Methods: This retrospective observational analysis included patients who underwent skin cancer HDR-BT Freiburg flap treatment between 2019 and 2023.
Oculodermal melanocytosis in Asian Indian patients: Prevalence, clinical presentation, and association with choroidal melanoma.
Indian J Ophthalmol
January 2025
The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, Telangana, India.
Objective: To study the prevalence, clinical presentation, treatment, and follow-up of ocular (dermal) melanocytosis (ODM) and its association with choroidal melanoma (CM) in Asian Indian patients.
Methods: This was a retrospective case series of patients with ODM conducted in a quaternary eye care center.
Results: Of the total 1.
Sensitivity of contributing factors to heterogeneity corrections in dosimetry of ocular brachytherapy using iodine-125 COMS plaques.
J Contemp Brachytherapy
October 2024
Department of Radiation Oncology, East Carolina University, Greenville, North Carolina, USA.
Purpose: To investigate sensitivity of contributing factors to heterogeneity corrections in ocular brachytherapy using iodine-125 (I) Collaborative Ocular Melanoma Study (COMS) plaques.
Material And Methods: Using egs_brachy, Monte Carlo (MC) simulations were performed for I COMS plaques (model: IsoAid IAI-125A). Homogeneous dose (D) was estimated under the American Association of Physicists in Medicine Task Group-43 assumptions, with 85 Gy prescribed to a 5 mm depth.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!